ranbaxy in norway: The Norwegian Appeals Court ruled that Ranbaxy Laboratories Ltd's generic version of Lipitor did not infringe Pfizer Inc's patents. Ranbaxy says they will now be able to market their products in Norway. Pfizer markets its cholesterol-lowering drug Atorvastatin as Lipitor. The court ruled that three Pfizer patents covering intermediate compounds used to make Atorvastatin, the active ingredients in Liptor, would not be infringed by the sale of a Ranbaxy's generic product in Norway. The two companies have been involved in a patent battle in various markets across the globe.